Literature DB >> 7639012

Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence.

M Gesemann1, N Scheiermann.   

Abstract

Hepatitis B vaccine-induced antibodies (anti-HBs) were quantified in 35 subjects (study group) and in an additional 24-59 subjects (controls) during a period of 82 months after vaccination against hepatitis B and the values used as a basis to develop a logarithmic formula to describe the post-booster antibody kinetics. The actual anti-HBs titres are shown to be proportional to the peak titre one month post-booster but inversely proportional to the number of months between the time of booster and of retesting. Using this model and an anti-HBs quantification more than a month post-booster, the individual persistence of vaccine-induced anti-HBs antibodies can be calculated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639012     DOI: 10.1016/0264-410x(94)00010-k

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Immune response against HBsAg vaccine.

Authors:  Maria Cristina Honorati; Andrea Facchini
Journal:  World J Gastroenterol       Date:  1998-12       Impact factor: 5.742

Review 2.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

3.  A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B.

Authors:  M C Honorati; A Palareti; P Dolzani; C A Busachi; R Rizzoli; A Facchini
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

4.  Long-term follow-up of Hepatitis B Surface antibody levels in subjects receiving universal Hepatitis B vaccination in infancy in an area of hyperendemicity: correlation between radioimmunoassay and enzyme immunoassay.

Authors:  Ching-Wen Wang; Li-Chieh Wang; Mei-Hwei Chang; Yen-Hsuan Ni; Huey-Ling Chen; Hong-Yuan Hsu; Ding-Shin Chen
Journal:  Clin Diagn Lab Immunol       Date:  2005-12

5.  Long term protection after hepatitis B vaccination.

Authors:  Sandra Puvacić; Jelena Ravlija; Zlatko Puvacić; Ivan Curić
Journal:  Bosn J Basic Med Sci       Date:  2005-08       Impact factor: 3.363

6.  Immunogenicity and safety of high-dose hepatitis B vaccine among drug users: A randomized, open-labeled, blank-controlled trial.

Authors:  Yongliang Feng; Jing Shi; Linying Gao; Tian Yao; Dan Feng; Dan Luo; Zhansheng Li; Yawei Zhang; Fuzhen Wang; Fuqiang Cui; Li Li; Xiaofeng Liang; Suping Wang
Journal:  Hum Vaccin Immunother       Date:  2017-03-16       Impact factor: 3.452

7.  The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy.

Authors:  Masoomeh Bagheri-Jamebozorgi; Jila Keshavarz; Maryam Nemati; Saeed Mohammadi-Hossainabad; Mohammad-Taghi Rezayati; Mohsen Nejad-Ghaderi; Ahmad Jamalizadeh; Fazel Shokri; Abdollah Jafarzadeh
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Antibody response to revaccination among adult non-responders to primary Hepatitis B vaccination in China.

Authors:  Li Zhang; Jiaye Liu; Jingjing Lu; Bingyu Yan; Lizhi Song; Li Li; Fuqiang Cui; Guomin Zhang; Fuzhen Wang; Xiaofeng Liang; Aiqiang Xu
Journal:  Hum Vaccin Immunother       Date:  2015-08-07       Impact factor: 3.452

9.  Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia.

Authors:  Kalifa Bojang; Paul Milligan; Margaret Pinder; Tom Doherty; Amanda Leach; Opokua Ofori-Anyinam; Marc Lievens; Kent Kester; Kurt Schaecher; W Ripley Ballou; Joe Cohen
Journal:  Hum Vaccin       Date:  2009-04-22

Review 10.  Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1.

Authors:  Jennifer A Whitaker; Nadine G Rouphael; Srilatha Edupuganti; Lilin Lai; Mark J Mulligan
Journal:  Lancet Infect Dis       Date:  2012-12       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.